We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Moleculin Biotech (MBRX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Moleculin Biotech is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MBRX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for MBRX's full-year earnings has moved 9.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, MBRX has gained about 24.58% so far this year. Meanwhile, stocks in the Medical group have lost about 2.74% on average. As we can see, Moleculin Biotech is performing better than its sector in the calendar year.
Breaking things down more, MBRX is a member of the Medical - Biomedical and Genetics industry, which includes 384 individual companies and currently sits at #10 in the Zacks Industry Rank. Stocks in this group have gained about 3.51% so far this year, so MBRX is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MBRX. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Moleculin Biotech (MBRX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Moleculin Biotech is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MBRX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for MBRX's full-year earnings has moved 9.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, MBRX has gained about 24.58% so far this year. Meanwhile, stocks in the Medical group have lost about 2.74% on average. As we can see, Moleculin Biotech is performing better than its sector in the calendar year.
Breaking things down more, MBRX is a member of the Medical - Biomedical and Genetics industry, which includes 384 individual companies and currently sits at #10 in the Zacks Industry Rank. Stocks in this group have gained about 3.51% so far this year, so MBRX is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MBRX. The stock will be looking to continue its solid performance.